Fresh analysis indicates that individuals who come off new slimming jabs like semaglutide or tirzepatide may regain lost weight far faster than those who stop conventional lifestyle plans.
Findings released in a prominent medical journal demonstrates that while obese individuals can lose a large proportion of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month after stopping.
"People buying these treatments should be cognizant of the potential of rapid rebound weight gain when the therapy concludes," stated lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a reversion to pre-treatment weight in about one and a half years.
Comparing Therapies
The research, which looked at 37 of studies involving thousands of patients, compared the effects of these new drugs with conventional dieting.
Researchers note that individuals who shed pounds through dieting typically experience a less rapid creep back—around 0.1 kg a month—once they finish.
Understanding the Rapid Rebound
Experts suggest the way of the drugs is key to understanding the accelerated weight return.
GLP-1 drugs imitate a body's own chemical called GLP-1, which controls hunger.
"Long-term administration of the hormone levels several times higher than the body's typical production could lead to the system to produce less of its own natural GLP-1, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication leads to appetite is uncontrolled, making excessive eating much more probable."
A Chronic Disease?
The NHS advise the jabs for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Many experts contend that, due to the significant potential of weight regain, the therapy should be considered long-term.
This opinion is supported by pharmaceutical companies, who state that the results "highlight the chronic character of obesity," comparing it to managing conditions like diabetes.
Patient Testimonies
Users who have discontinued the medication report a powerful resurgence of appetite.
"I experienced a trigger that goes on and you're instantly ravenous," described a patient.
The struggle is exacerbated if patients have not established sustainable dietary or behavioural changes during treatment.
Widespread Adoption
Survey data suggest that a significant number of people in the UK have used these injections in the last 12 months, with demand continuing to grow.
- Adoption is more common among women than males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic solution and lasting health benefits hinges on combined behavioural changes.
